

# Ultra scale-down approaches to enhance the creation of bioprocesses at scale: impacts of process shear stress and early recovery stages

Andrea CME Rayat, Alex Chatel, Mike Hoare and Gary J Lye



The sensitivity of biological materials to shear stress conditions encountered during large-scale bioprocessing makes successful scale up from the bench challenging. Ultra scale-down technologies seek to use just millilitre quantities to enhance our understanding of the impact of the process environment as a basis for process optimisation. They can help speed translation of new biological discoveries to market and reduce risks encountered in scale up. They are important both as process discovery tools and as preparative tools to yield material for study of subsequent stages. In this review the focus is on the early recovery stages post fermentation or cell culture and in particular the use of continuous-flow and dead-end centrifugation integrated with preparative stages (e.g. flocculation) and subsequent depth filtration. Examples range from therapeutic antibodies, to rationally engineered (synthetic biology) host strains, to stem cells for therapy.

## Address

The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Gower St, London WC1E 6BT, UK

Corresponding author: Lye, Gary J ([g.lye@ucl.ac.uk](mailto:g.lye@ucl.ac.uk))

**Current Opinion in Chemical Engineering** 2016, **14**:150–157

This review comes from a themed issue on **Biotechnology and bioprocess engineering**

Edited by **Eleftherios Terry Papoutsakis** and **Nigel J Titchener-Hooker**

For a complete overview see the [Issue](#) and the [Editorial](#)

Available online 26th October 2016

<http://dx.doi.org/10.1016/j.coche.2016.09.012>

2211-3398/© 2016 Published by Elsevier Ltd.

## Bench-scale technologies for application of process-scale shear stress

All stages of an industrial sequence for the preparation of a biological therapeutic involve exposure of the material to various forms of stress, that is, mechanical or different types of hydrodynamic stress. In this review we are concerned with hydrodynamic stress as commonly occurs during flow within and through process equipment. In some cases the stress applied is similar at bench and industrial scale but often the stress applied at full scale far exceeds that at bench scale. Notable examples include pump transfers (e.g. [1]), flow through valves, feed within

continuous-flow high speed centrifuges [2] and the discharge of supernatant and sediment phases [3]. There are also examples of high stress occurring at bench scale not reproduced at full scale, for example, flow through pipettes [4], mixing using surface mounted (grinding) magnetic stirrers.

A key objective of ultra scale-down technologies (Figure 1) is to determine if the biological material is susceptible to applied process shear stress, and if so to quantify the effect of shear stress on the material and on the performance of subsequent unit operations, for example, filtration or chromatography. Two geometries are commonly used at bench scale to expose process material to hydrodynamic shear stress:


- Capillary flow — here, exposure to stress occurs on entry to and exit from the capillary, flow through the capillary and impact of the discharged jet on the collection surface. The flow in the capillary progresses from undeveloped to laminar rather than turbulent flow as opposed to turbulent flow in many large-scale applications.
- Rotating disc flow — here, flow occurs over the rotating disc surface housed within a chamber (Figure 2). The greatest stress occurs at the disc tip with both rotational flow and radial flow impacting on the chamber surface. The flow is generally highly turbulent but heterogeneous in nature.

Examples of materials studied include for capillary flow: mammalian cells (e.g. [5,6,7]) and cells for therapy [8,9]; and for rotational flow: precipitates (e.g. [10]), mammalian cells (e.g. [11]), cells for therapy (e.g. [12]), adjuvants (e.g. [13]), flocs (e.g. [14]), phages (e.g. [15]) and antibodies (e.g. [16,17]).

## Bench-scale technologies for centrifuge ultra-scale down

All bioprocess stages pose particular challenges in achieving successful scale-down in a conventional sense, that is, maintaining geometric similarity. For example, for packed bed chromatography the need to maintain the same bed height and superficial velocity means that scale down is ultimately limited by the column diameter beyond which it is necessary to reduce column height and hence residence time for binding or superficial flow velocity. Similarly for membrane separation when it is

Figure 1



The role of ultra scale-down in speeding bioprocess development. Process characterisation is needed to evaluate manufacturability of a new product or to evaluate the process impact of introducing a new host, that is, through screening or rational engineering (synthetic biology) approaches. (1) Specification of whole bioprocess from fermentation/cell culture to formulation. (2) Identification and characterisation of critical regimes, for example, of high shear stress, long hold times, hostile interfaces, etc. (3) Use of ultra scale-down methods to prepare material and for testing of sensitivity to critical regimes and impact on rest of process. (4) Use of new insight to respecify process sequence, for example, remove regimes resulting in product damage. (5) With increased confidence in ability of ultra scale-down methods to predict pilot and full-scale operations focus on process refinement rather than process reinvention.

no longer possible to maintain the same membrane length and hence profile of transmembrane pressure drops. However, the translation from small (ca 10s mL) bench scale (where scale down rules cannot be followed) to pilot scale is eased by the availability of large (ca 100s mL) capacity bench-scale devices which can keep to scale down rules [18–20]. Such devices are not available for pilot-scale continuous-flow centrifugation and, here, scale down requires a major change in geometry for operation at scales of less than 1000s mL.

The classical approach for scale down of full-scale ( $FS$ ) centrifugation is based on the definition of an equivalent area of a gravity settling pond,  $\Sigma_{FS}$ . Here, the geometry and rotational speed of a centrifuge is used to compute the settling of particles during suspension flow through

the centrifuge. A characteristic clarification performance is used to define  $\Sigma_{FS}$  for the centrifuge. This theoretical analysis needs to be accompanied by an experimental study to help characterise non-idealities in flow, for example, due to turbulence or due to particle resuspension. Within this review this calibration factor is incorporated within the value of  $\Sigma_{FS}$ . On this basis, the centrifuge performance is simply characterised by the ratio of flow rate,  $Q_{FS}$ , to settling area. While this does not allow scaling based on dewatering or on sediment capacity, it does provide a useful basis for clarification, the main function of many centrifugation stages during recovery.

The translation from a full-scale continuous-flow centrifuge to a bench-scale batch test tube centrifuge is a considerable challenge. The equivalent settling area,  $\Sigma_{USD}$ , of a test tube housed in a centrifuge head is defined in terms of the inner and outer radii of the suspension ( $R_1$  and  $R_2$ ) and the rotational speed,  $N$ , and using the same separating criteria as for the full-scale centrifuge. The suspension volume,  $V_{USD}$ , and the spin time,  $t_{USD}$ , give the equivalent flow rate such that we have the following expressions:


$$\Sigma_{USD} = \frac{V_{USD}(2\pi N)^2}{6g \ln(2R_2/(R_2 + R_1))}$$

$$S = f\left(\frac{V_{USD}}{t_{USD} \Sigma_{USD}}\right) = f\left(\frac{Q_{FS}}{\Sigma_{FS}}\right)$$

where  $S$  is solids remaining in supernatant. Typical values of  $(V_{USD}/t_{USD} \Sigma_{USD})$  range from  $1 \times 10^{-9} \text{ m}^3 \text{ m}^{-2} \text{ s}^{-1}$  to mimic a high speed centrifuge operating at low flow rate to  $100 \times 10^{-9} \text{ m}^3 \text{ m}^{-2} \text{ s}^{-1}$  to mimic a high speed centrifuge operating at high flow rate, the upper limit to recover low density difference 0.1–100  $\mu\text{m}$  sized biological particles. Typical values of  $\Sigma_{USD}$  are 0.01–0.5  $\text{m}^2$ , typical values of  $\Sigma_{FS}$  for pilot-scale centrifuges are 500–5000  $\text{m}^2$ .

Careful attention is needed to make sure the acceleration and deceleration phases of bench-scale centrifuge operation do not unduly affect the extent of clarification (see [21] for correction factors) and that supernatant withdrawal does not lead to resuspension of the often loosely compacted sediment [22]. However, the greatest challenge is the nature of the feed to a continuous centrifuge and the impact of process shear stress. Incoming material is subject to considerable acceleration forces and estimated maximum energy dissipation rates range from 45 W/mL to 530 W/mL [2,14]. These are considerably higher stresses than those which occur in preceding stages such as reactors for cell growth, or for cell lysate, precipitate, floc or crystal preparation and are probably of similar orders of magnitude as occur in devices used for mechanical cell disruption (high pressure or bead mill homogenisers). The design of

Figure 2



An ultra representation of energy dissipation rate a ratescale-down approach to investigating process material shear sensitivity at the laboratory scale. This is achieved using a rotating disc device (kompAs™) which produces defined levels of hydrodynamic shear stress (energy dissipation rate: 1–1000 W mL<sup>-1</sup>), comparable to those found in industrial equipment such as centrifuges or pumps. The total volume of process material required (20 mL) is sufficient for further studies such as USD centrifugation and/or USD filtration as well as analytical measurements of the product and impurities. Note that the colour scale is a logarithmic representation of energy dissipation rate.

the feed zone to the centrifuge determines the level of shear stress, for example, hermetic or hydrohermetic designs to eliminate or minimise the air core in the entry feed zone allow more gentle acceleration of the feed suspension. It is important to determine if this is a critical design feature for the material being processed as results of primary recovery operation could vary [10,11<sup>\*</sup>].

Other sources of stress can include the discharge of the supernatant that can be via a centripetal pump into a pipe or by high velocity flow over a weir into a capture vessel. The discharge of the solids can either be via intermittent high velocity nozzle discharge [3] or continuous nozzle discharge at a velocity determined by the centrifuge design, for example, discharge at the outer bowl [23] or via the bowl axis with a relationship determined by the extent of dewatering achieved [24,25]. The resuspension of high viscosity sediment can also be a high stress process especially via manual pipetting at bench scale [4<sup>\*</sup>].

The relative importance of these various stress effects is determined by the material being processed and the product form/location, for example, supernatant or sediment and the place of the centrifuge operation in the bioprocess sequence. At present, in the absence of a generic design procedure, this is best studied via particular examples of process sequences.

### Ultra scale-down studies of bioprocess sequences

A general overview of scale down of biochemical engineering options has been provided elsewhere [26]; the focus here is on use of ultra scale-down and the enhanced bioprocess understanding which is gained in particular downstream processing sequences in the early recovery stages.

### Interaction of homogenisation and centrifugation

One route for the recovery of intracellular products is via high pressure homogenisation followed by centrifugal removal of the cell debris. Adaptive focused acoustics has been used to mimic the high pressure homogenisation of recombinant *Escherichia coli* for the release of an antibody fragment and the formation of cell debris of specific size distribution as well as the release and disruption of nucleic acids [27]. A homogeniser operating on a recycle loop followed by a disc stack centrifuge for debris removal was successfully mimicked by a combination of bench-scale adaptive focused acoustics and ultra scale-down centrifugation (as described above) to demonstrate how challenging is the removal of micronized cell debris formed from the need for multiple recycles to achieve near complete protein product release [28]. The impact has also been demonstrated of cell wall weakening during extended fermentation leading to reduced centrifuge

clarification performance [29]. Recently, synthetic biology approaches have been studied using ultra scale-down methods to rationally engineer cells with improved characteristics for bioprocessing. In one example, the use of a strain engineered with an inducible nuclease has been shown using to enhance the processability of recombinant *E. coli* homogenates [30]. Similarly, ultra scale-down methods predicted the effect of the micellar state of lipids and their removal to avoid fouling for hydrophobic resins [31].

### Interaction of flocculation, centrifugation and depth filtration


Flocculation in this review relates to use of polymeric reagents (e.g. polyethyleneimine (PEI) or polydiallyldimethylammonium chloride (PDADMAC)) for the selective precipitation (e.g. of nucleic acids) and aggregation (e.g. of colloidal proteins, lipopolysaccharides, colloidal proteins) of biological contaminants (e.g. [14,32,33–35]). It is used in a process sequence to offer a rapid clean-up of a complex bioprocess stream before progression to a sensitive chromatographic or selective adsorption separation stage. The ultra scale-down of floc preparation follows the same rules as for a precipitate (see below) with regards to mixing conditions and times. The ability to work at small scale allows study of the effect of floc agent properties (e.g. molecular weight, concentration, degree

of molecular unravelling etc.), as well as sensitivity to mixing conditions [36]. Key findings include the use of flocculating agents to remove the presence of small (micron sized) particles to form large flocs that are sensitive to the effects of shear stress. However, the micron sized particles do not reappear and, because the particles remain well above the critical size for centrifugal removal, high levels of clarification are achieved (Figure 3a). For example, in one study combining ultra scale-down flocculation, shear stress and centrifugation the use of flocculation was predicted to reduce contaminant carry-over by >50-fold [14] with greater ease of depth filtration of the subsequent supernatant [14,37]. This was then verified at pilot scale [14,32,37]. Verification at pilot scale of ultra scale-down predictions is critical to provide confidence for design predictions and has been achieved for other flocculated systems (e.g. [38]).

### Interaction of precipitation and centrifugation

In the context of this review, precipitation is generally achieved via a change in the process environment, for example, pH, ionic strength, dielectric constant etc. or combinations thereof. Precipitation continues to be explored to provide novel solutions to bioprocessing (e.g. [39–41]). The product or the contaminants may be subject to precipitation and then generally removal/recovery by centrifugation [21] or possibly filtration [20] especially

Figure 3



(a) Flocculation is used to process an autolysed *E. coli* cell broth removing all sub-micron cell debris and also precipitating soluble contaminants, for example, nucleic acids, while the exposure (for 20 s) to high shear stress decreases the average particle size, there is no reappearance of sub-micron particles leading to ultra scale-down predictions of high levels of clarification in continuous flow centrifugation [14] that are verified at pilot scale [37]. (b) The fine particles formed as a result of the application of shear stress (20 s) on mammalian cell broth will be difficult to remove by centrifugation and subsequent filtration [11].

if the product remains in the soluble phase. The control of the properties of the precipitate is achieved by the choice of reactor conditions of the mean velocity gradient ( $G = (P/V\mu)^{0.5}$ ) where  $P$  is power dissipated in a volume,  $V$ , with suspension viscosity,  $\mu$ , and residence time,  $t$ . The precipitate particle size is generally inversely proportional to  $G$ . The dimensionless Camp number ( $Ca = Gt$ ) determines the strength of the precipitate with maximum resistance to disruption to shear stress being observed for  $Ca > 10^5$  [42]. However, even after such ageing the precipitate is still strongly susceptible to shear stress induced break up, for example, in pumps or in centrifuge feed zones. Examples of successful USD prediction of precipitation and precipitate recovery by centrifugation have been achieved, for example, salt precipitation of microbial proteins or ethanol precipitation of blood plasma proteins [10].

#### Interaction of suspension cell culture, harvest, centrifugation and filtration


The production of monoclonal antibodies and other protein products via mammalian cell culture involves firstly a sequence of solid-liquid separation stages to prepare a clarified broth suitable for chromatographic or adsorption based separation. The cells are cultured in a relatively low shear stress environment and high levels of shear stress may lead to considerable attrition (Figure 3b) and release of intracellular components. The impact of such disruption on the centrifugal clarification of cell broth has been studied with the use of a high stress feed zone predicted to lead to over 10-fold increase in solids carryover compared with no shear stress (Figure 4). The use of a low stress feed

zone reduces such carryover very significantly [11\*,22,43,44] and using ultra scale-down filtration tools [45–47] is shown to enhance the performance of subsequent filtrations stages [48]. The correct back pressuring of a centrifuge to maintain a low shear stress (hydrohermetic) feed zone may be defined as a Critical Process Parameter when the validation of such a bioprocess is addressed. The impact of such shear stress on the protein product might need to be considered, for example, for a monoclonal antibody no impact on glycosylation pattern was observed but the presence of half antibodies increased [49] while for a fusion protein a large impact on extent of glycosylation was observed [50\*]. Improvements in mammalian cell biology have been predicted to be best realised by use of low shear stress processing options [51]. The effect of surface interactions under shear stress has been reported for antibodies leading to loss of functionality in solutions without the appropriate protective agents [16,17,52].

#### Interaction of surface-attached cell culture, centrifugation and resuspension

The preparation of cells for therapy is one of the most challenging areas in terms of understanding the impact of the processing environment on the product [53]. For allogeneic therapies, such as multi-potent adult stem cells (MPACs), the scale of production is often near the limit of analytical techniques so the challenge is to understand the effect of the processing environment. For autologous therapies, such as induced pluripotent stem cells (iPS cells) or T-cells, there is also the challenge of scale-down. As might be expected different cell lines respond very differently to the application of process stress [12,54]

Figure 4



Ultra scale-down shear stress analysis along with ultra scale-down centrifugation was used to predict the carryover of solids during clarification of industrial scale mammalian cell culture broths. The predicted large increase in solids carryover was verified at pilot scale ( $\Sigma_{FS} = \sim 2500 m^2$ ,  $Q_{FS} = 80-500 L/h$ ), as was the effect of increasing the flowrate through the centrifuge. The use of no shear bench-scale centrifugation significantly underestimates the performance of even low-shear pilot-scale centrifugation [11\*]. Solid lines are fits by regression of the ultra scale-down data, dashed lines are extrapolation of relationship; the lines for high and low shear ultra scale-down data fits are transposed to show match with pilot-scale results.

and for a particular cell line the cell passage number, generation number and method of growth all affect the response to shear stress [55]. Capillary based studies have been used to reduce the number of cells required for process characterisation [9]. As predicted [7,56,57] the main reason for damage is due to extensional flow at the capillary entrance but careful computational analysis of the particle and fluid dynamics is needed to identify regimes of exposure of cells to stress. The translation of such results has led to an understanding of the reasons for cell loss during operation of scale-down mimics of dead-end centrifugation where the combination of pipette flow velocities and sediment rheology [58] led to stresses exceeding the predicted process stress for damage and solutions to reduce such stress [4<sup>\*</sup>]. Capillary flow has been used to gain further understanding of the reasons for other causes of cell damage [8,59]. Similar ultra scale-down tools are needed to explore new options for cell recovery, for example, cross flow filtration or expanded bed centrifugation [4<sup>\*</sup>] and washing and administration.

## Conclusions

An increasing number of stages in a bioprocess are becoming accessible to investigation using ultra scale-down methods, including continuous operations. This review has focused on one of the major challenges for scale down, that is, centrifugation, especially as a key stage between cell culture/fermentation and chromatographic purification. Examples are provided of the successful application of ultra scale-down methods for a range of bioprocess sequences.

The ability to complete ultra scale-down studies of whole bioprocess sequences will allow low cost development of a full-scale process while assurance is awaited of the clinical safety and efficacy of the candidate therapy. Then it will be possible to move at speed to large-scale manufacture.

As more complex therapies become the deliverable of value, the use of ultra scale-down to help enhance process development at low cost is likely to become increasingly important. Ultra scale-down methods also provide a quantitative and predictive methodology by which to assess the benefits of host cell engineering (synthetic biology) on whole bioprocess performance.

## Acknowledgements

The funding of the UK Engineering and Physical Sciences Research Council (EPSRC) for the Innovative Manufacturing Research Centre in Bioprocessing hosted at UCL is gratefully acknowledged as is the support of the collaborating companies including: BioProducts Laboratories, BioVex, Eli Lilly, FujiFilm Diosynth, GE Healthcare, GSK, ImmunoBiology, Lonza Biologics, MedImmune, Merck, Novo Nordisk, OnyVax, Pall Life Sciences, Pfizer, Puridify, The Automation Partnership (TAP, now Sartorius Stedim), UCB, Westfalia (now GEA).

The support of the Higher Education Funding Council for England (HEFCE) Catalyst Fund to support access to ultra scale-down technologies and the knowledge transfer activities is also gratefully acknowledged.

## References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Zhang H, Kong S, Booth A, Boushaba R, Levy MS, Hoare M: **Prediction of shear damage of plasmid DNA in pump and centrifuge operations using an ultra scale-down device.** *Biotechnol Prog* 2007, **23**:858-865.
2. Boychyn M, Yim SS, Bracewell DG, Hoare M: **Performance prediction of industrial centrifuges using scale-down models.** *Bioprocess Biosyst Eng* 2004, **26**:385-391.
3. Chan G, Booth AJ, Mannweiler K, Hoare M: **Ultra scale-down studies of the effect of flow and impact conditions during E. coli cell processing.** *Biotechnol Bioeng* 2006, **95**:671-683.
4. Delahaye M, Lawrence K, Ward SJ, Hoare M: **An ultra scale-down analysis of the recovery by dead-end centrifugation of human cells for therapy.** *Biotechnol Bioeng* 2015, **112**:997-1011.
- The application of ultra scale-down shear stress testing to resolve process effects determining the recovery of intact cells.
5. Mollet M, Godoy-Silva R, Chalmers JJ: **Acute hydrodynamic forces induce apoptosis: a complex question.** *Biotechnol Bioeng* 2007, **98**:772-788.
- The importance is illustrated of different hydrodynamic regimes on cell integrity.
6. Mollet M, Godoy-Silva R, Berdugo C, Chalmers JJ: **Computer simulations of the energy dissipation rate in a fluorescence activated cell sorter: implications to cells.** *Biotechnol Bioeng* 2008, **100**:260-272.
7. Tanzeglock T, Soos M, Stephanopoulos G, Morbidelli M: **Induction of mammalian cell death by simple shear and extensional flows.** *Biotechnol Bioeng* 2009, **104**:360-370.
8. Zoro BJH, Owen S, Drake RAL, Mason C, Hoare M: **Regenerative medicine bioprocessing: concentration and behaviour of adherent cell suspensions and pastes.** *Biotechnol Bioeng* 2009, **103**:1236-1247.
9. Acosta-Martinez JP, Papantoniou I, Lawrence K, Ward S, Hoare M: **Ultra scale-down analysis of the bioprocessing of whole human cells as a basis for cancer vaccines.** *Biotechnol Bioeng* 2010, **107**:953-963.
10. Boychyn M, Yim SS, Shamlou PA, Hoare M: **Characterisation of flow intensity in continuous centrifuges for the development of laboratory mimics.** *Chem Eng Sci* 2000, **56**:4759-4770.
11. Hutchinson N, Bingham N, Murrell N, Hoare M: **Shear stress analysis of mammalian cell suspensions for prediction of industrial centrifugation and its verification.** *Biotechnol Bioeng* 2006, **95**:483-491.
- The demonstration of verification of ultra scale-down methods at industrial scale for various designs of centrifuge feed zone.
12. McCoy R, Ward S, Hoare M: **Ultra scale-down studies of the effect of shear on cell quality; processing of a human cell line for cancer vaccine therapy.** *Biotechnol Prog* 2009, **25**:1448-1458.
13. Kolade OO, Jin W, Tengroth C, Green KD, Bracewell DG: **Shear effects on aluminium phosphate adjuvant particle properties in vaccine drug products.** *J Pharm Sci* 2015, **104**:378-387.
14. Chatel A, Kumpalaume P, Hoare M: **An ultra scale-down characterisation of the impact of conditioning methods for harvested cell broths on clarification by continuous centrifugation – recovery of domain antibodies from rec E. coli.** *Biotechnol Bioeng* 2014, **111**:913-924.
15. Branston S, Stanley E, Ward J, Keshavarz-Moore E: **Study of robustness of filamentous bacteriophages for industrial applications.** *Biotechnol Bioeng* 2011, **108**:1468-1472.
16. Biddlecombe JG, Craig AV, Zhang H, Uddin S, Mulot S, Fish BC, Bracewell DG: **Determining antibody stability: creation of solid-liquid interfacial effects within a high shear environment.** *Biotechnol Prog* 2007, **23**:1218-1222.

17. Biddlecombe JG, Smith G, Uddin S, Mulot S, Spencer D, Gee C, Fish BC, Bracewell DG: **Factors influencing antibody stability at solid-liquid interfaces in a high shear environment.** *Biotechnol Prog* 2009, **25**:1499-1507.
  18. Rayat ACME, Lye GJ, Micheletti M: **A novel microscale crossflow device for the rapid evaluation of microfiltration processes.** *J Membr Sci* 2014, **452**:284-293.
  19. Ma G, Aucamp J, Eardly-Patel R, Craig A, Hoare M, Zhou Y: **Mimic of a large-scale diafiltration process by using an ultra scale-down rotating disc filter.** *Biotechnol Prog* 2010, **26**:466-476.
  20. Reynolds T, Boychyn M, Sanderson T, Bulmer M, More J, Hoare M: **Scale-down of continuous filtration for rapid bioprocess design: recovery and dewatering of protein precipitate suspensions.** *Biotechnol Bioeng* 2003, **83**:454-464.
  21. Maybury JP, Hoare M, Dunnill P: **The use of laboratory centrifugation studies to predict performance of industrial machines; studies of shear-insensitive and shear-sensitive materials.** *Biotechnol Bioeng* 2000, **67**:265-273.
  22. Tait AS, Aucamp JP, Bugeon A, Hoare M: **Ultra scale-down prediction using microwell technology of the industrial scale clarification characteristics by centrifugation of mammalian cell broths.** *Biotechnol Bioeng* 2009, **104**:321-331.
  23. Aucamp JP, Davies R, Hallet D, Weiss A, Titchener-Hooker NJ: **Integration of host strain bioengineering and bioprocess development using ultra-scale down studies to select the optimum combination: an antibody fragment primary recovery case study.** *Biotechnol Bioeng* 2014, **111**:1971-1981.
  24. Lopes AG, Keshavarz-Moore E: **Prediction and verification of centrifugal dewatering of *P. pastoris* fermentation cultures using an ultra scale-down approach.** *Biotechnol Bioeng* 2012, **109**:2039-2047.
  25. Lopes AG, Kha N, Liddell J, Keshavarz-Moore E: **An ultra scale-down approach to assess the impact of the choice of recombinant *P. pastoris* strain on dewatering performance in centrifuges.** *Biotechnol Prog* 2012, **28**:1029-1036.
  26. Titchener-Hooker NJ, Dunnill P, Hoare M: **Micro biochemical engineering to accelerate the design of industrial-scale downstream processes for biopharmaceutical proteins.** *Biotechnol Bioeng* 2008, **100**:473-487.
  27. Li Q, Aucamp J, Tang A, Chatel A, Hoare M: **Use of focused acoustics for cell disruption to provide ultra scale-down insights of microbial homogenization and its bioprocess impact – recovery of antibody fragments from rec *E. coli*.** *Biotechnol Bioeng* 2012, **109**:2059-2069.
  28. Li Q, Mannall GJ, Hoare M: **An ultra scale-down approach to study the interaction of fermentation, homogenisation and centrifugation for antibody fragment recovery from rec *E. coli*.** *Biotechnol Bioeng* 2013, **110**:2150-2160.
  29. Perez-Pardo MA, Ali S, Balasundaram B, Mannall GJ, Baganz F, Bracewell DG: **Assessment of the manufacturability of *Escherichia coli* high cell density fermentations.** *Biotechnol Prog* 2011, **27**:1488-1496.
  30. Balasundaram B, Nesbeth D, Ward JM, Keshavarz-Moore E, Bracewell DG: **Step change in the efficiency of centrifugation through cell engineering: co-expression of *Staphylococcal* nuclease to reduce the viscosity of the bioprocess feedstock.** *Biotechnol Bioeng* 2009, **104**:134-142.
  31. Bracewell DG, Boychyn M, Baldascini H, Storey SA, Bulmer M, More J, Hoare M: **Impact of clarification strategy on chromatographic separations: pre-processing of cell homogenates.** *Biotechnol Bioeng* 2008, **100**:941-949.
  32. Voulgaris I, Finka G, Uden M, Hoare M: **Enhancing the selective extracellular location of a recombinant *E. coli* domain antibody by management of fermentation conditions.** *Appl Microbiol Biotechnol* 2015, **99**:8441-8453.
  33. McDonald P, Victa C, Carter Franklin JN, Fahrner R: **Selective antibody precipitation using polyelectrolytes. A novel approach to the purification of mAbs.** *Biotechnol Bioeng* 2009, **102**:1141-1151.
  34. Westoby M, Chrostowski J, de Vilmorin P, Smelko JP, Romero JK: **Effects of solution environment on mammalian cell fermentation broth properties: enhanced impurity removal and clarification performance.** *Biotechnol Bioeng* 2011, **108**:50-58.
  35. Kang YK, Hamzik J, Felo M, Qi B, Lee J, Ng S, Liebisch G, Shanehsaz B, Singh R, Persaud K, Ludwig L, Balderes P: **Development of a novel and efficient cell culture flocculation process using a stimulus responsive polymer to streamline antibody purification processes.** *Biotechnol Bioeng* 2013, **110**:2928-2937.
  36. Espuny Garcia del Real G, Davies J, Bracewell DG: **Scale-down characterization of post-centrifuge flocculation processes for high-throughput process development.** *Biotechnol Bioeng* 2014, **111**:2486-2498.
  37. Voulgaris I, Chatel A, Hoare M, Finka G, Uden M: **Evaluation of options for harvest of a recombinant *E. coli* fermentation producing a domain antibody using ultra scale-down techniques and pilot-scale verification.** *Biotechnol Prog* 2016, **32**:382-392.
- The application of ultra scale-down shear stress, centrifugation and filtration to address a challenging downstream process sequence.
38. Berrill A, Ho SV, Bracewell DG: **Ultra scale-down to define and improve the relationship between flocculation and disc-stack centrifugation.** *Biotechnol Prog* 2008, **24**:426-431.
  39. Capito F, Bauer J, Rapp A, Schroter C, Kolmar H, Stanislawski B: **Feasibility study of semi-selective protein precipitation with salt-tolerant copolymers for industrial purification of therapeutic antibodies.** *Biotechnol Bioeng* 2013, **110**:2915-2927.
  40. Brodsky Y, Zhang C, Yigzaw Y, Vedantham G: **Caprylic acid precipitation method for impurity reduction: an alternative to conventional chromatography for monoclonal antibody purification.** *Biotechnol Bioeng* 2013, **109**:2589-2598.
  41. Chhatre S, Pampel L, Titchener-Hooker NJ: **Integrated use of ultra scale-down and financial modelling to identify optimal conditions for the precipitation and centrifugal recovery of milk proteins.** *Biotechnol Prog* 2011, **27**:998-1008.
  42. Bell DJ, Dunnill P: **Shear disruption of soya protein precipitate particles and the effect of ageing in a stirred tank.** *Biotechnol Bioeng* 1982, **24**:1271-1285.
  43. Zaman F, Allan CM, Ho SV: **Ultra scale-down approaches for clarification of mammalian cell culture broths in disc-stack centrifuges.** *Biotechnol Prog* 2009, **25**:1709-1716.
- A comparison of different methods of applying shear stress and the resulting prediction of full scale recovery.
44. Westoby M, Rogers JK, Haverstock R, Romero J, Pieracci J: **Modelling industrial centrifugation of mammalian cell culture using a capillary based scale-down system.** *Biotechnol Bioeng* 2011, **108**:989-998.
  45. Jackson NB, Liddell JM, Lye GJ: **An automated microscale technique for the quantitative and parallel analysis of microfiltration operations.** *J Membrane Sci* 2006, **276**:31-34.
  46. Rayat ACME, Micheletti M, Lye GJ: **Evaluation of cell disruption effects on primary recovery of antibody fragments using microscale bioprocessing techniques.** *Biotechnol Prog* 2010, **26**:1312-1321.
  47. Islam RS, Tisi D, Levy MS, Lye GJ: **Framework for the rapid optimization of soluble protein expression in *Escherichia coli*: combining microscale experiments and statistical experimental design.** *Biotechnol Prog* 2007, **23**:785-793.
  48. Joseph A, Kenty B, Mollet M, Hwang K, Rose S, Goldrick S, Bender J, Farid SS, Titchener-Hooker NJ: **A scale-down mimic for mapping the process performance of centrifugation, depth, and sterile filtration.** *Biotechnol Bioeng* 2016, **113**:1934-1941.
  49. Reid CQ, Tait A, Baldascini H, Mohindra A, Racher A, Bilsborough S, Smales CM, Hoare M: **Rapid whole monoclonal antibody analysis by mass spectrometry: an ultra scale-down study of the effect of harvesting by centrifugation on the post-translational modification profile.** *Biotechnol Bioeng* 2010, **107**:85-95.

50. Lau EC, Kong SY, McNulty S, Entwistle C, McIligorm A, Dalton K, Hoare M: **An ultra scale-down characterisation of low shear primary recovery stages to enhance selectivity of fusion protein recovery from its molecular variants.** *Biotechnol Bioeng* 2013, **110**:1973-1983.
- The demonstration of the importance of low shear stress operations for certain therapeutic candidates.
51. Potty ASR, Xenopoulos A, Patel S, Prentice H, DiLeo A: **The effect of antiapoptosis genes on clarification performance.** *Biotechnol Prog* 2014, **30**:100-107.
52. Tavakoli-Keshe R, Phillips JJ, Turner R, Bracewell DG: **Understanding the relationship between biotherapeutic protein stability and solid-liquid interfacial shear in constant region mutants of IgG1 and IgG4.** *J Pharm Sci* 2014, **103**:437-444.
53. Cunha B, Peixoto C, Silva MM, Carrondo MJT, Serra M, Alves PM: **Filtration methodologies for the clarification and concentration of human mesenchymal stem cells.** *J Membrane Sci* 2015, **478**:117-129.
54. McCoy R, Ward S, Hoare M: **Sub-population analysis of human cancer vaccine cells – ultra scale-down characterisation of response to shear.** *Biotechnol Bioeng* 2010, **106**:584-597.
55. Dhondalay GK, Lawrence K, Ward S, Ball G, Hoare M: **Relationship between preparation of cells for therapy and cell quality using artificial neural network analysis.** *Artif Intell Med* 2014, **62**:119-127.
56. Godoy-Silva R, Chalmers JJ, Casnocha SA, Bass LA, Ma N: **Physiological responses of CHO cells to repetitive hydrodynamic stress.** *Biotechnol Bioeng* 2009, **103**:1103-1117.
57. Godoy-Silva R, Mollet M, Chalmers JJ: **Evaluation of the effect of chronic hydrodynamic stresses on cultures of suspended CHO-6E6 cells.** *Biotechnol Bioeng* 2009, **102**:1119-1130.
58. Zoro BJH, Owen S, Drake RAL, Hoare M: **The impact of process stress on suspended anchorage-dependent mammalian cells as an indicator of likely challenges for regenerative medicines.** *Biotechnol Bioeng* 2008, **99**:468-474.
59. Papantoniou I, Hoare M, Veraitch FS: **The release of single cells from embryoid bodies in a capillary flow device.** *Chem Eng Sci* 2010, **66**:570-581.